Targeting minimal residual disease: a path to cure?
Therapeutics that block kinases, transcriptional modifiers, immune checkpoints and other biological vulnerabilities are transforming cancer treatment. As a result, many patients achieve dramatic responses, including complete radiographical or pathological remission, yet retain minimal residual disea...
| Main Authors: | , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | en_US |
| Published: |
Nature Publishing Group
2018
|
| Online Access: | http://hdl.handle.net/1721.1/118912 https://orcid.org/0000-0001-5223-9433 |
| _version_ | 1826204478175444992 |
|---|---|
| author | Luskin, Marlise R. Murakami, Mark A. Weinstock, David M. Manalis, Scott R |
| author2 | Massachusetts Institute of Technology. Department of Biological Engineering |
| author_facet | Massachusetts Institute of Technology. Department of Biological Engineering Luskin, Marlise R. Murakami, Mark A. Weinstock, David M. Manalis, Scott R |
| author_sort | Luskin, Marlise R. |
| collection | MIT |
| description | Therapeutics that block kinases, transcriptional modifiers, immune checkpoints and other biological vulnerabilities are transforming cancer treatment. As a result, many patients achieve dramatic responses, including complete radiographical or pathological remission, yet retain minimal residual disease (MRD), which results in relapse. New functional approaches can characterize clonal heterogeneity and predict therapeutic sensitivity of MRD at a single-cell level. Preliminary evidence suggests that iterative detection, profiling and targeting of MRD would meaningfully improve outcomes and may even lead to cure. |
| first_indexed | 2024-09-23T12:56:14Z |
| format | Article |
| id | mit-1721.1/118912 |
| institution | Massachusetts Institute of Technology |
| language | en_US |
| last_indexed | 2024-09-23T12:56:14Z |
| publishDate | 2018 |
| publisher | Nature Publishing Group |
| record_format | dspace |
| spelling | mit-1721.1/1189122022-10-01T11:59:36Z Targeting minimal residual disease: a path to cure? Luskin, Marlise R. Murakami, Mark A. Weinstock, David M. Manalis, Scott R Massachusetts Institute of Technology. Department of Biological Engineering Massachusetts Institute of Technology. Department of Mechanical Engineering Program in Media Arts and Sciences (Massachusetts Institute of Technology) Manalis, Scott R Manalis, Scott R Therapeutics that block kinases, transcriptional modifiers, immune checkpoints and other biological vulnerabilities are transforming cancer treatment. As a result, many patients achieve dramatic responses, including complete radiographical or pathological remission, yet retain minimal residual disease (MRD), which results in relapse. New functional approaches can characterize clonal heterogeneity and predict therapeutic sensitivity of MRD at a single-cell level. Preliminary evidence suggests that iterative detection, profiling and targeting of MRD would meaningfully improve outcomes and may even lead to cure. Koch Institute-Dana-Farber/Harvard Cancer Center Bridge Project National Cancer Institute (U.S.) (R33 CA191143) National Cancer Institute (U.S.). Cancer Systems Biology Consortium (U54 CA217377) 2018-11-06T15:18:56Z 2018-11-06T15:18:56Z 2018-01 Article http://purl.org/eprint/type/JournalArticle 1474-175X 1474-1768 http://hdl.handle.net/1721.1/118912 Luskin, Marlise R., Mark A. Murakami, Scott R. Manalis, and David M. Weinstock. “Targeting Minimal Residual Disease: a Path to Cure?” Nature Reviews Cancer 18, no. 4 (January 29, 2018): 255–263. doi:10.1038/nrc.2017.125. https://orcid.org/0000-0001-5223-9433 en_US https://doi.org/10.1038/nrc.2017.125 Nature Reviews Cancer Creative Commons Attribution-Noncommercial-Share Alike http://creativecommons.org/licenses/by-nc-sa/4.0/ application/pdf Nature Publishing Group Prof. Manalis via Howard Silver |
| spellingShingle | Luskin, Marlise R. Murakami, Mark A. Weinstock, David M. Manalis, Scott R Targeting minimal residual disease: a path to cure? |
| title | Targeting minimal residual disease: a path to cure? |
| title_full | Targeting minimal residual disease: a path to cure? |
| title_fullStr | Targeting minimal residual disease: a path to cure? |
| title_full_unstemmed | Targeting minimal residual disease: a path to cure? |
| title_short | Targeting minimal residual disease: a path to cure? |
| title_sort | targeting minimal residual disease a path to cure |
| url | http://hdl.handle.net/1721.1/118912 https://orcid.org/0000-0001-5223-9433 |
| work_keys_str_mv | AT luskinmarliser targetingminimalresidualdiseaseapathtocure AT murakamimarka targetingminimalresidualdiseaseapathtocure AT weinstockdavidm targetingminimalresidualdiseaseapathtocure AT manalisscottr targetingminimalresidualdiseaseapathtocure |